ARS Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | — | $230.8M | $71.0M |
| FY2024 | $0 | $256.8M | $50.8M |
| FY2025 | $96.4M | $114.3M | $41.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | — | $230.8M | $71.0M |
| FY2024 | $0 | $256.8M | $50.8M |
| FY2025 | $96.4M | $114.3M | $41.3M |